Conference Coverage

Adding rapid trichomonas test to the sexually transmitted infection panel boosts rapid treatment


 

AT THE 2014 STD PREVENTION CONFERENCE

ATLANTA – Adding a rapid Trichomonas vaginalis test to the adolescent sexually transmitted infection laboratory regimen facilitated on-site diagnosis and treatment at an urban medical center emergency department.

The OSOM rapid trichomonas test provided point of care testing results in 10 minutes, with a sensitivity of 83% and specificity of 99%, Dr. Heather Territo reported in a poster at a conference on STD prevention sponsored by the Centers for Disease Control and Prevention. The prevalence of Trichomonas vaginalis approaches 25% in inner-city adolescents. Prior studies have demonstrated an association between Trichomonas vaginalis and cervical neoplasia, enhanced HIV transmission, and pregnancy complications.

Courtesy CDC

The prevalence of Trichomonas vaginalis approaches 25% in inner-city adolescents.

After routine Trichomonas vaginalis testing was implemented at the Women’s and Children’s Hospital of Buffalo, N.Y., in November 2011, 212 females aged 13-20 years were tested in the following year; 13.6% tested positive by rapid test and 15.5% by nucleic acid amplification test (NAAT). In the year before routine testing was implemented, 31 of 234 patients were tested, based on a retrospective chart review. Treatment was administered to 24% and to 7% of patients during the respective study periods, said Dr. Territo of the hospital’s division of emergency medicine.

Additionally, two positive results were found in 20 males tested.

In the emergency department, Trichomonas vaginalis is often diagnosed on the basis of clinical findings; the positive predictive value of this approach is less than 50%. Direct microscopy of vaginal secretions has a sensitivity of about 60%-70%.

The rapid test and the NAAT test results were concordant in 178 of 188 cases (94.6%). Ten of the 33 positive NAAT tests (30%) were negative on the rapid test.

Dr. Territo reported having no relevant financial disclosures.


Recommended Reading

Renal protective effect found for acetaminophen in ICU sepsis
MDedge Emergency Medicine
FDA approves dalbavancin for acute bacterial skin infections
MDedge Emergency Medicine
Hypertonic saline indications for bronchiolitis lack evidence for clear guidance
MDedge Emergency Medicine
CDC: Illinois man cleared of MERS-CoV; not infected by Indiana patient
MDedge Emergency Medicine
Seven percent of patients with life-threatening skin reactions have another episode
MDedge Emergency Medicine
Azithromycin provides a net benefit in older pneumonia inpatients
MDedge Emergency Medicine
MERS virus can be transmitted from camels to humans, case report shows
MDedge Emergency Medicine
No need to hospitalize febrile immunosuppressed kids who are otherwise well
MDedge Emergency Medicine
WHO: Basic infection control key to stemming MERS-CoV transmission
MDedge Emergency Medicine
Close contacts of U.S. MERS-CoV cases uninfected
MDedge Emergency Medicine